The New England journal of medicine, 2021-01, Vol.384 (4), p.325-334
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
- Ist Teil von
- The New England journal of medicine, 2021-01, Vol.384 (4), p.325-334
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients with pulmonary hypertension due to interstitial lung disease were randomly assigned to inhaled treprostinil or placebo. At 16 weeks, there was a significant improvement in exercise capacity with inhaled treprostinil as compared with placebo as assessed by a 6-minute walk test.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2008470Titel-ID: cdi_proquest_journals_2481872233
- Format
- –
- Schlagworte
- Administration, Inhalation, Adult, Adverse events, Aged, Aged, 80 and over, Antihypertensive Agents - adverse effects, Antihypertensive Agents - therapeutic use, Brain natriuretic peptide, Catheterization, Clinical trials, Cough, Diarrhea, Double-Blind Method, Drug dosages, Dyspnea, Epoprostenol - adverse effects, Epoprostenol - analogs & derivatives, Epoprostenol - therapeutic use, Exercise Tolerance - drug effects, Female, Humans, Hypertension, Hypertension, Pulmonary - drug therapy, Hypertension, Pulmonary - etiology, Hypertension, Pulmonary - physiopathology, Laboratories, Least-Squares Analysis, Lung diseases, Lung Diseases, Interstitial - complications, Male, Middle Aged, Nausea, Patients, Placebos, Pulmonary hypertension, Pulse oximetry, Quality of Life, Respiration, Statistical analysis, Walk Test